On the evening of November 13, the Chinese Medicine Co., Ltd. and Shanghai Medicine were announced to be cited.Its unanimous actor.
From the latest shareholding ratio, Xinhua Insurance and its consistent actions are for the first time with Chinese medicine shares and Shanghai Medicine.
Two pharmaceutical companies are cited at the same time
Insurance, all occurred on November 12.
Specifically, on November 12, Xinhua Insurance increased its holdings of 1.499 million shares of Chinese medicine shares, and the increase in Shanghai Pharmaceutical A shares of 9.9998 million shares and H shares of H sharesRead 1.5 million shares.
After completing the above -mentioned increase, Xinhua Insurance and its consistent actors hold 5.07%and 5.05%of the shares of Chinese medicine shares and Shanghai Medicine, respectively.
Xinhua Insurance said that the license is based on the future development prospects of long -term optimism in the medical and health industry, which is intended to share the long -term dividend of the future development of the medical and health industry.
Sinopharm shares are based on "medicine circulation", covering the national drug distribution, pharmaceutical retail, pharmaceutical industry, pharmaceutical logistics and other businesses.In the first three quarters of 2024, the companys operating income was 38.029 billion yuan, an increase of 4.10%year -on -year; the net profit of home mother was 1.481 billion yuan, an increase of 1.30%year -on -year.
Source: Sinopharm shares 2024 Journey
Shanghai Medicines main business covers medicineIndustry and pharmaceutical business, ranked 411th in the Fortune 500 in the World Fortune in 2024.In the first three quarters of 2024, the companys operating income was 209.629 billion yuan, a year -on -year increase of 6.14%; the net profit of home mother was 4.054 billion yuan, an increase of 6.78%year -on -year.Industry insiders remind that the performance of the two pharmaceutical companies still achieve year-on-year growth.Overall negative growth.
Closing on November 13, the total market value of Chinese medicine shares and Shanghai Medicine was 25.970 billion yuan and 69.25 billion yuan.
The number of insurances in the year has exceeded last year
According to incomplete statistics, since 2024, insurance capital has been licensed 13 times, while the number of licenses in 2023, 2022, and 2021 is 9 times, 5 times, and 5 times, respectively, and 5 times, 5 times, and 5 times, and 5 times, 5 times, and 5 times, and 5 times, 5 times, and 5 times, 5 times, and 5 times, and 5 times, 5 times, and 5 times, and 5 times, 5 times, and 5 times, and 5 times, 5 times, and 5 times, and 5 times, 5 times, and 5 times, and 5 times, 5 times, and 5 times, and 5 times, 5 times, and 5 times, 5 times, and 5 times, 5 times, and 5 times, and 5 times, 5 times, and 5 times.5 times.
In summary, the target company of insurance capital is A -share and Hong Kong stock companies involved in environmental protection, infrastructure, new energy, medicine and other industries.
Taking the Great Wall Life as an example, the Jiangnan water affairs and urban hair environment in mid -May mention the strong confidence in the future development prospects of Jiangnan water and urban development environment, as well as the twoThe companys leading position in the industry is recognized.
Industry insiders have reminded that insurance capital has become an important shareholder of listed companies through licenses, which not only provides long -term stable financial support for listed companies, but also effectively alleviates its own asset allocation pressureEssence
At the same time, insurance capital increases its holdings of listed companies, which reflects the important functions of financial service entities.The previous meeting of the Political Bureau of the Central Committee of the Central Committee proposed "Giving Patience Capital", and the new "National Nine Articles" also mentioned guiding insurance to the city.
Industry insiders believe that overall, the proportion of investment in insurance equity is still relatively low.Under the influence of factors such as regulatory policies and investment income from insurance capital, insurance capital is expected to increase investment in equity.
Editor -in -chief: Zhao Hanyu Text Editor: Dong Siyun Title Picture Source: Photo of the top of the view
Source: Author: China Fund News
